FreeCME

Virtual Tumor Board™: EGFR Mutation Matters: Optimizing Therapy by EGFR Mutation Subtype and Co-Mutations

/ Print /
| ShareMore
/ Text Size +
12/16/21 7:00 am EDT
Virtual Webinar
United States


Virtual Tumor Board™: EGFR Mutation Matters: Optimizing Therapy by EGFR Mutation Subtype and Co-Mutations

The management of EGFR-mutated non–small cell lung cancer (NSCLC) has evolved dramatically in recent years, with new effective therapies for different patient subgroups being introduced across the continuum of care. Effective treatment of this group of lung cancers requires careful coordination of different specialties in the multidisciplinary team. In particular, accurate molecular assessment is essential to identify the best treatment options, both in the newly diagnosed and relapsed disease settings.

Learning Objectives

Upon completion of this activity, participants will be able to:

Describe EGFR mutation subtypes and corresponding predictive/prognostic characteristics

Evaluate outcomes in different EGFR mutations subtypes with different EGFR inhibitor-based monotherapy and combination regimens

Identify high-risk genomic comutations in patients with EGFR mutationpositive NSCLC

Apply mutational profiling, including EGFR mutation subtype and high-risk genetic features, to optimize therapy in patients with NSCLC and an EGFR mutation

 Date

December 16, 2021
7:00 - 8:30 AM EST
Live, Interactive Webcast!

 Chair

 Suresh S. Ramalingam, MD, FACP, FASCO

Suresh S. Ramalingam, MD, FACP, FASCO
Professor of Hematology and Medical Oncology
Roberto C. Goizueta Distinguished Chair for Cancer Research
Director, Division of Medical Oncology
Deputy Director
Winship Cancer Institute of Emory University School of Medicine
Atlanta, GA